home / stock / pvct / pvct news

PVCT News and Press, Provectus Biopharmaceuticals Inc From 03/23/21

Stock Information
Company Name: Provectus Biopharmaceuticals Inc
Stock Symbol: PVCT
Market: OTC
Website: provectusbio.com
Menu
PVCT PVCT Quote PVCT Short PVCT News PVCT Articles PVCT Message Board
Get PVCT Alerts

News, Short Squeeze, Breakout and More Instantly...
PVCT - Provectus Biopharmaceuticals Receives Notice of Allowance for Refractory Pediatric Solid Tumor Cancer Monotherapy and Combination Therapy Patent for PV-10® Immunotherapy from United States Patent and Trademark Office

KNOXVILLE, TN, March 23, 2021 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that the United States Patent and Trademark Office (USPTO) has allowed US patent application 16/412,872, which covers the use of intralesional (aka intratumoral) PV-10, an injectable formulation of Pro...
PVCT - Provectus Biopharmaceuticals Announces Release of Preprint Manuscript Describing Preclinical Study of PV-10® Immunotherapy and Chemotherapy for Treatment of Pancreatic Cancer

KNOXVILLE, TN, Jan. 20, 2021 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that H. Lee Moffitt Cancer Center (Moffitt) has released a manuscript preprint describing how investigational autolytic cancer immunotherapy PV-10, an injectable formulation of Provectus’ proprie...

PVCT - Provectus Biopharmaceuticals Announces Oral Presentation of Updated Data from Combination Therapy Trial of PV-10® and Keytruda® for Checkpoint-Refractory Advanced Cutaneous Melanoma at Melanoma Bridge 2020

29% ORR (7% CR) and 57% DCR (RECIST 1.1) 75% ORR in anti-PD-1-refractory patients 56% DCR (11% CR) in patients refractory to anti-CTLA-4 and anti-PD-1 combination therapy Presentation delivered by Moffitt’s Jonathan Zager, MD KNOXVILLE, TN, Dec. 07, 2020 (GLOBE NE...

PVCT - Provectus Biopharmaceuticals Announces Presentation of PV-10® Pancreatic Cancer Data at 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting

KNOXVILLE, TN, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that H. Lee Moffitt Cancer Center (Moffitt) presented non-clinical data from ongoing research on investigational autolytic cancer immunotherapy PV-10, an injectable formulation of Provectus' proprietary...
PVCT - Provectus Biopharmaceuticals Announces Acceptance of PV-10® Melanoma Abstract for Oral Presentation at Melanoma Bridge 2020

KNOXVILLE, TN, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that data from the Company's ongoing Phase 1b/2 study of autolytic cancer immunotherapy PV-10, an injectable formulation of Provectus' proprietary small molecule rose bengal disodium (RBD), in combinati...

PVCT - Provectus Biopharmaceuticals Announces Acceptance of PV-10® Pancreatic Cancer Abstract at 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting

KNOXVILLE, TN, Oct. 15, 2020 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that H. Lee Moffitt Cancer Center will present non-clinical data from ongoing research on investigational autolytic cancer immunotherapy PV-10, an injectable formulation of Provectus' proprietary rose b...

PVCT - Provectus concludes patient enrollment in early-stage neuroendocrine tumors study

Provectus ([[PVCT]] -2.9%) has completed enrollment of 12 patients for its Phase 1 of cancer immunotherapy PV-10, an injectable formulation of its proprietary rose bengal disodium, for the treatment of symptomatic neuroendocrine tumors metastatic to the liver, refractory to somatostatin ...
PVCT - Provectus Biopharmaceuticals Completes Enrollment of PV-10® Study for Treatment of Symptomatic Neuroendocrine Tumors Metastatic to the Liver Refractory to Somatostatin Analogs and Peptide Receptor Radionuclide Therapy

Company plans to seek end-of-phase meeting with Australia’s Therapeutic Goods Administration in Q1 2021 KNOXVILLE, TN, Oct. 05, 2020 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced the completion of enrollment of 12 patients into the Company’s Phase 1 stu...

PVCT - Provectus Biopharmceuticals Highlights Stage IV M1d Patient Outcome from Combination Therapy Trial of PV-10® and KEYTRUDA® for Checkpoint-Refractory Advanced Cutaneous Melanoma at ESMO Virtual Congress 2020

Complete response of all injected lesions Regression of non-injected inguinal node, lung, and brain metastases Expanded data set of trial subject provided KNOXVILLE, TN, Sept. 21, 2020 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today highlighted the clinical outcome of a ...

PVCT - Provectus Biopharmaceuticals Highlights Stage IV M1c Patient Outcome from Combination Therapy Trial of PV-10® and KEYTRUDA® for Checkpoint-Naïve Advanced Cutaneous Melanoma at ESMO Virtual Congress 2020

Near-resolution of tumor burden, including extensive visceral hepatic disease Expanded data set of trial subject provided KNOXVILLE, TN, Sept. 21, 2020 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today highlighted the clinical outcome of a Stage IV M1c patient (Subject 0112) in ...
Previous 10 Next 10